非小细胞肺癌术后放疗的临床意义

目的　观察非小细胞肺癌 (NSCLC)术后放疗的价值。材料与方法　回顾性分析我院自 1985 - 0 1～1995 - 12经手术治疗的非小细胞肺癌 170例 ,分为单纯手术组 (单术组 ) 94例 ,手术加放疗组 (术放组 ) 76例 ,单术组Ⅰ、Ⅱ期病例略多。单术组术后未再接受其他治疗 ;术放组术后 2～ 4周进行放疗 ,6MV -X线常规分割外放疗DT5 0GY～ 60GY。分别统计 2组间 5年总生存率、5年无瘤生存率、局部复发率和远处转移率 ,为了排除 2组间病期早晚对顾后的影响 ,还单独分析了Ⅲ期病例 2组间各分析指标的差别 ,统计采用X2 检验。结果　单术组和术放组的 5年总生存率分别为 31 9% (30 / 94 ) ,31 6% (2 4 / 76) ,(P >0 0 5 )。 5年无瘤生存率分别为 2 5 5 % (2 4 / 94 ) ,2 8 9% (2 6/ 76) ,(P >0 0 5 )。 2组局部复发率分别为 31 9% (30 / 94 ) ,2 3 7% (18/ 76) ,(P>0 0 5 )。远转率分别为 4 8 9% (4 6/ 94 ) ,4 4 7% (34 / 76) (P >0 0 5 )。单纯分析Ⅲ期病例 ,单术组和术放组 5年无瘤生存率分别为 2 5 % (14 / 5 6) ,38 7% (2 4 / 62 ) (P >0 0 5 )。 2组局部复发率分别为 39 3% (2 2 / 5 6) ,2 4 2 % (15 / 62 ) ,(0 0 5

0

Clinical Analysis of Radiate Treatment of NSCLC

Object To observe the value of the radiate treatment in post-operational NSCLC. Material and Methods Retrospectively analysis of 170 NSCLC cases during operation in our hospital from January 1985 to December 1995,which are divided into operation team (94 cases) and operation plus radiation team (76 cases). There are more 1,2 stage cases in operation group. And the cases in this team did not accept other treatment any more. The case in the operation plus radiation will accept radiate treatment in 2～4 weeks after operation,6MV-X line routine division radiate treatment DT50Cy-60GY. Stat separately the total five-year viability and the five-year-non-tumor viability, the rate of local recur and the matastatic rate. To eliminate the affect of the ---to the prognosis in the two teams, we analysis lonely the difference among every ratios of the two teams in the 3 expect, adopted x2 test. Results The total five-year survival rate of the operation team and the operation plus radiation team are 31.9%(30/94)and 31.6%(24/76),(p>0.05), the five-year-non-tumor survival rate of these two teams are 25.5%(24/94) and 28.9%(26/76),(p>0.05). The rate of local recur are 31.9%(30/94) and 23.7%(18/76),(p.0.05).The matastatic rates are 48.9%(46/94) and 44.7%(34/760,(p>0.05).After analysis alone the cases in 3except , the five-year-non-tumor survival rate of these two teams are25%(14/56) and 38.7%(24/62)(p>0.05). the rate of local recur of the two teams are 39.3%(22/56) and 24.2%(15/62),(0.050.05).1 case in the operation team died of the operational syndrome, 4 cases in the operation plus radiation team died of radiated pneumonia, and 2 died of infection in lung.Inclusion NSCLC does not fit the routine radiate treatment after operation. It is clear that the radiate treatment after operation has the negative effect to the total viability in the cases of 1or 2 except, and the rate of local recur will be reduced by the radiate treatment after operation in the cases of 3 except.